Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Kiromic BioPharma, Inc.

< Previous 1 2 Next >
Kiromic BioPharma Reports Tumor Volume Decrease in Two Patients Enrolled in Deltacel-01
From Kiromic BioPharma, Inc.
Via Business Wire
Tickers KRBP
Kiromic BioPharma Reports 32% Decrease in Tumor Volume Eight Months Post-Treatment in Fourth Patient Enrolled in Deltacel-01
From Kiromic BioPharma, Inc.
Via Business Wire
Tickers KRBP
Kiromic BioPharma Announces Settlement of Previously Disclosed SEC Investigation
From Kiromic BioPharma, Inc.
Via Business Wire
Tickers KRBP
Kiromic BioPharma Reports Favorable Ongoing Clinical Results From Fourth and Sixth Patients Enrolled in Deltacel-01
From Kiromic BioPharma, Inc.
Via Business Wire
Tickers KRBP
Kiromic BioPharma Reports Favorable 10-Month Follow-Up Results for the First Patient Treated in its Deltacel-01 Clinical Trial
From Kiromic BioPharma, Inc.
Via Business Wire
Tickers KRBP
Kiromic BioPharma Activates the University of Arizona Cancer Center as the Fifth Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 Trial
From Kiromic BioPharma, Inc.
Via Business Wire
Tickers KRBP
Kiromic BioPharma Advances Deltacel-01 Into Expansion Phase Following Safety Monitoring Committee’s Unanimous Recommendation
From Kiromic BioPharma, Inc.
Via Business Wire
Tickers KRBP
Kiromic BioPharma’s Deltacel Receives FDA Fast Track Designation
From Kiromic BioPharma, Inc.
Via Business Wire
Tickers KRBP
Kiromic BioPharma Provides Update on Part 1 of the Deltacel-01 Trial
From Kiromic BioPharma, Inc.
Via Business Wire
Tickers KRBP
Kiromic BioPharma Reports 20% Tumor Size Reduction at Eight Months in First Patient Enrolled in Deltacel-01
From Kiromic BioPharma, Inc.
Via Business Wire
Tickers KRBP
Kiromic BioPharma to Advance Deltacel-01 Clinical Trial to Part 2, Expansion Phase
From Kiromic BioPharma, Inc.
Via Business Wire
Tickers KRBP
Kiromic BioPharma Provides Updates on its Deltacel-01 Clinical Trial
From Kiromic BioPharma, Inc.
Via Business Wire
Tickers KRBP
Kiromic BioPharma Reports Six-Month Results from First Patient Enrolled in Deltacel-01 Clinical Trial
From Kiromic BioPharma, Inc.
Via Business Wire
Tickers KRBP
Kiromic BioPharma Reports Favorable Results at Six Weeks from Fourth Patient in Deltacel-01 Clinical Trial
From Kiromic BioPharma, Inc.
Via Business Wire
Tickers KRBP
Kiromic BioPharma Adds UPMC as Fourth Deltacel-01 Clinical Trial Site
From Kiromic BioPharma, Inc.
Via Business Wire
Tickers KRBP
Kiromic BioPharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients
From Kiromic BioPharma, Inc.
Via Business Wire
Tickers KRBP
Kiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial
From Kiromic BioPharma, Inc.
Via Business Wire
Tickers KRBP
Early Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial
From Kiromic BioPharma, Inc.
Via Business Wire
Tickers KRBP
Kiromic BioPharma Adds Virginia Oncology Associates, PC as the Second Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 Trial
From Kiromic BioPharma, Inc.
Via Business Wire
Tickers KRBP
Kiromic BioPharma to Present at the OTC Markets’ Virtual Life Science Investor Forum on March 7th
From Kiromic BioPharma, Inc.
Via Business Wire
Tickers KRBP
Results from First Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial Indicate Tumor Reduction at Two Months
From Kiromic BioPharma, Inc.
Via Business Wire
Tickers KRBP
Kiromic BioPharma Reports Favorable Early Efficacy Results from First Patient in Deltacel-01 Phase 1 Clinical Trial in Non-Small Cell Lung Cancer
From Kiromic BioPharma, Inc.
Via Business Wire
Tickers KRBP
Kiromic BioPharma Reports Favorable Early Safety and Tolerability Data from First Patient Enrolled in the Phase 1 Deltacel-01 Clinical Trial
From Kiromic BioPharma, Inc.
Via Business Wire
Tickers KRBP
Kiromic BioPharma Announces First Patient Dosed in Phase 1 Study Evaluating Deltacel™ for the Treatment of Non-Small Cell Lung Cancer
From Kiromic BioPharma, Inc.
Via Business Wire
Tickers KRBP
Kiromic BioPharma Announces Uplisting to OTCQB Market
From Kiromic BioPharma, Inc.
Via Business Wire
Tickers KRBP OTC
Kiromic BioPharma Announces Deltacel™ Phase 1 Clinical Trial Enters Patient Recruitment Phase at Beverly Hills Cancer Center
From Kiromic BioPharma, Inc.
Via Business Wire
Tickers KRBP OTC
Kiromic BioPharma and Beverly Hills Cancer Center Enter Clinical Trial Agreement
From Kiromic BioPharma, Inc.
Via Business Wire
Tickers KRBP OTC
Kiromic BioPharma Welcomes Two New Directors to its Board
From Kiromic BioPharma, Inc.
Via Business Wire
Tickers KRBP
Kiromic BioPharma Announces FDA Authorization of IND to Initiate Phase 1 Clinical Trial Evaluating Deltacel in Non-Small Cell Lung Cancer
From Kiromic BioPharma, Inc.
Via Business Wire
Tickers KRBP
Kiromic BioPharma Submits Investigational New Drug Application for Phase 1 Trial with Deltacel for Non-Small Cell Lung Cancer
From Kiromic BioPharma, Inc.
Via Business Wire
Tickers KRBP
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.